The impactful factors influencing the growth of the global viral gastroenteritis market during the forecast period are growing prevalence of gastrointestinal diseases, accessibility of cost-effective treatment, and the extensive research and development activities towards internal medicine. Additionally, there is a growing demand for the introduction of new drugs for the treatment of viral gastroenteritis.
According to a report by Market Research future (MRFR), the global viral gastroenteritis market is expected to register a remarkable market valuation at 7.5% CAGR over the evaluation period.
The severely competitive market scenario is expected to act as a substantial barrier for new entrants in the global viral gastroenteritis market over the review period.
The global viral gastroenteritis market is segmented on the basis of the type of virus, diagnosis, drug, indication, and end-user.
Based on the type of virus, the viral gastroenteritis market has been segmented into astrovirus, enteric adenovirus, norovirus, and rotavirus.
On the basis of diagnosis, the global viral gastroenteritis market has been segmented into the physical examination and rapid stool tests.
Based on the indication, the global viral gastroenteritis market has been segmented into antacids, antibiotics, antimotility agents, laxatives, and others.
Based on end-user, the global viral gastroenteritis market is segmented into ambulatory care centers, clinics, diagnostic centers, hospitals, pharmaceutical companies.
Based on the region, the market has been segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas account for the largest region in the global viral gastroenteritis market and are expected to retain the significant market share over the evaluation period. This is attributable to the rising prevalence of viral gastroenteritis in the region, along with the presence of a key market player in developed countries such as the US and Canada.
The Asia Pacific is accounted for the fastest growing region over the forecast period. The significant growth of the Asia Pacific region is credited to the increasing expenditure of the governments towards the improvement of the healthcare sector in developing countries such as India and China. Additionally, the growing prevalence of chronic diseases has led to an increasing demand for technologically advanced treatment and diagnostic measures, which is expected to consequently drive the market growth in the region over the review period.
The middle east and Africa region accounts for the smallest market share in the global viral gastroenteritis market over the forecast period, owing to the poor healthcare sector and weak economic growth in Africa. Additionally, the political unrest in a particular part of Africa and the middle east is also expected to slow the growth of the market in the region. The government efforts towards the improvement of the healthcare sector have risen expenditure, research and development activities and the presence of global nonprofit organizations in the region, which is likely to contribute significantly to the viral gastroenteritis market in Africa over the forecast period. Moreover, the developing countries of the Middle East such as the United Arab Emirates, Saudi Arabia,Kuwait and Turkey with improving healthcare infrastructure, are expected to contribute to the majority of the market share over the assessment period
the key players in the global viral gastroenteritis market are Abbott (U.S.), Allergan (Ireland), AstraZeneca (U.K), Bayer AG (Germany), GlaxoSmithKline (U.S.), Janssen Global Services, LLC U.S.), Sanofi (France), Takeda Pharmaceutical (Japan), and Valeant Pharmaceuticals International Inc. (U.S.).